<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4263EBC0-36F8-4775-A2F5-2E8F91AAB578"><gtr:id>4263EBC0-36F8-4775-A2F5-2E8F91AAB578</gtr:id><gtr:name>French Agency for Food, Environmental and Occupational Health &amp; Safety (ANSES)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Infectious and Tropical Diseases</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4263EBC0-36F8-4775-A2F5-2E8F91AAB578"><gtr:id>4263EBC0-36F8-4775-A2F5-2E8F91AAB578</gtr:id><gtr:name>French Agency for Food, Environmental and Occupational Health &amp; Safety (ANSES)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/87278C4F-B243-4CDD-9541-75198D0B1CAC"><gtr:id>87278C4F-B243-4CDD-9541-75198D0B1CAC</gtr:id><gtr:firstName>Polly</gtr:firstName><gtr:surname>Roy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FJ021342%2F1"><gtr:id>465BD83A-9589-4532-8608-C62D77236D2A</gtr:id><gtr:title>Realising the potential of a genetically engineered and uniquely cross protective vaccine for Bluetongue disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/J021342/1</gtr:grantReference><gtr:abstractText>Bluetongue disease is a debilitating and, in severe cases, lethal, animal disease that is a major economic threat to livestock and agriculture. Current vaccines available for Bluetongue are not considered to be safe enough for widespread use. Our laboratory has developed a replication defective (DISC) virus that can be used safely as an alternative BTV vaccine with none of the existing issues. In order to commercialize this vaccine a number of optimizations are necessary. In particular, the stability of the specialized cells which support the growth of the vaccine virus will be optimized. Moreover, to ensure that the DISC virus does not change with time, we will monitor for potential changes in the growth of the virus, expression of virus proteins and genome. The optimal storage conditions for vaccine and number of dose required will be determined in sheep to ensure that protection afforded is maximized.</gtr:abstractText><gtr:fund><gtr:end>2014-02-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-09-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>137478</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>French Agency for Food, Environmental and Occupational Health &amp; Safety (ANSES)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Assessment of DISC Vaccines</gtr:description><gtr:id>E0918C3A-4225-4E3A-B2BC-54542232BA16</gtr:id><gtr:outcomeId>b9602836b9602854-1</gtr:outcomeId><gtr:piContribution>Vaccination and challenge studies using DISC vaccines.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Vaccine Centre Seminar-2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D84F0FCB-5C84-4BB1-93E1-54595CAF9E6E</gtr:id><gtr:impact>Present the results for the replication-deficient BTV strains in animal trials.</gtr:impact><gtr:outcomeId>58a4614f5d9e17.10900815</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PMB Seminar 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>16876C13-55F0-4189-A644-39CE4BE24E71</gtr:id><gtr:impact>Presentation of results for discussion with peer researchers</gtr:impact><gtr:outcomeId>58c7d9ba8ec492.61708202</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We have generated highly attenuated RG-based vaccines for BTV and currently trying to find interested industrial partner to test these vaccines in animals and to manufacture for marketing.</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>1FEA5A7E-0352-46BF-9B40-7B1DE7132993</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56dea1ab5f1d87.46871706</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>BTV DISC strains are a safe and effective vaccine against bluetongue disease with DIVA potential. The original DISC vaccine strains with GFP in S9 proved to be genetically stable, with alteration in dsRNA profile observed but no reversion to wild type. Therefore, a second generation DISC vaccine (DISC2) was developed and 7 vaccine strains (serotypes -1,-2,-4,-8,-9,-10 and -16) were generated. The DISC2 vaccine strains were genetically stable after continuous passage (up to 10 passages) with no recombination or reversion to wild type virus observed. The DISC2 viruses were highly stable and suitable for large scale production. The stable cell line BSR VP6, which is essential for DISC growth, had detectable VP6 expression and was able to successfully support high titre virus production after 10 or 15 passages in tissue culture. For the DISC vaccine to elicit protective immunity the infectivity of particles must be maintained, therefore optimal conditions for storage and transportation were investigated. We demonstrated that the DISC vaccine maintained infectivity when desiccated in the presence of trehalose. This condition removes the vaccine from cold-chain storage and transportation thus reducing costs of vaccine production. Furthermore, the effect of desiccation and trehalose did not affect the protective immune response of sheep upon vaccination.</gtr:description><gtr:exploitationPathways>The findings from this follow-on grant can be applied directly to the commercialisation of a BTV or other related virus vaccine by any industrial partner. We are currently seeking an industrial partner to commercially produce these BTV vaccine strains.</gtr:exploitationPathways><gtr:id>83B92ECC-7624-4601-AAEE-6D328CD6F527</gtr:id><gtr:outcomeId>r-4875920289.080516774cf5f6</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture/ Food and Drink,Manufacturing/ including Industrial Biotechology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Details of sheep antibodies pre- and post-challenge; antibody response to group specific protein (VP7) and development of neutralising antibodies for specific BTV serotypes.</gtr:description><gtr:id>74E74C57-A099-4A55-B8C0-5D914DC778CB</gtr:id><gtr:outcomeId>r-1678572792.26050972b1f67e0</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Antibodies pre and post challenge</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Details of sheep antibodies pre- and post-vaccination</gtr:description><gtr:id>5AE43A73-105E-4D13-9022-FF2F1BBA20CB</gtr:id><gtr:outcomeId>r-3653620987.8079792b1f68d0</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Antibodies pre and post vaccination</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A multiple mutated BTV segment S9 was designed in order to improve a new generation of vaccines. This new BTV-1 platform was name DISC 2.</gtr:description><gtr:id>985818D4-BCAD-414D-AF3E-8C4D9A56BC3A</gtr:id><gtr:impact>This new research tool has improve the genetic stability of replication deficient BTV strains that can be tested as vaccine candidates</gtr:impact><gtr:outcomeId>r-2885196099.882197ac78d84a</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DISC 2</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>For RNA-RNA interactions ssRNA segments, 150 ng linearized plasmid templates were transcribed either in pairs or combinations of multiple segments. RNA transcription was carried out in a buffer containing 40mM Tris, pH7.5; 10mM MgCl2; 20mM NaCl2, 3mM spermidine, 50mM DTT; 5mM each rNTPs; 10U RNase inhibitor and 40U of T7 RNA Polymerase (Thermo Scientific) for 3 h at 37&amp;deg;C followed by RNase free DNase 1 treatment. Immediately after DNase treatment, detection of RNA complexes was
done by electrophoretic mobility shift assay (EMSA). Electrophoresis gel was run for 180 min at 150 V in TBM buffer (45mM Tris, pH8.3; 43mM boric acid; 0.1mM MgCl2) and stained with 0.01% (w/v) ethidium bromide.</gtr:description><gtr:id>3DC470E0-7D09-400A-B0B8-F5C9E6FE6B45</gtr:id><gtr:impact>Understanding packaging signals is essential for development of antiviral reagents.</gtr:impact><gtr:outcomeId>58c6af38ed5294.05575755</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RNA-RNA interaction and electrophoretic mobility shift assay (EMSA)</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/pubmed/27736800</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Plasmid constructs (serotype specific exact copy and S9 deletion/mutations)</gtr:description><gtr:id>A67D4842-07AB-4A98-9222-840F98D915EE</gtr:id><gtr:impact>A range of mutation in BTV S9 (enconding VP6) were tested to generate cell lines and improve the reverse genetics system for BTV.</gtr:impact><gtr:outcomeId>r-7203640534.732157c6b55b54</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DNA Plasmid</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Set of constructs for E. Coli and Baculovirus expression of AHSV VP2 tip-domain:
Bacterial expression constructs:
pHis-GST-A1tip
pHis-Sumo-A1tip
pHis-Sumo-A1tip2
pET-TwinStrep-B1tip-Chis
pET-A1tip-Strep
pET-A1tip-FdSA

Baculovirus expression constructs:
pHT-HisTEV-A1VP2
pIP-A1tip-Strep
pIP-A1tip-FdSA</gtr:description><gtr:id>6EA52F0F-D51D-4A10-BCBD-71AEB199ED44</gtr:id><gtr:impact>The characterization of VP2 tip-domain is a powerful tool for virus - cellular receptor interaction studies.</gtr:impact><gtr:outcomeId>56d984bb6d3e51.86016967</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>AHSV1 and BTV1 VP2 tip-domain studies</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A range of reagents and conditions for storing vaccine strains was tested in order to optimise a formulation for the use of DISC viruses as vaccine</gtr:description><gtr:id>BAF52437-CEB4-4CDE-9561-0F02A0736B60</gtr:id><gtr:impact>Optimisation of transport and stability conditions for vaccine candidates is essential for a better cost-effective vaccine.</gtr:impact><gtr:outcomeId>r-2370438382.374531ac788f20</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Storing vaccine strains</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Data on BSR-VP6 cell line stability; number of passages that the cell line can be continually passaged and VP6 is detectable by western immunoblot and can support DISC virus growth.</gtr:description><gtr:id>A06AF360-C077-4A4B-81E7-ADA9F5FF9F7F</gtr:id><gtr:impact>This test was conducted in order to study the genetic stability of the stable cell line expressing BTV VP6 that can be used for growing disabled viruses, potential vaccines.</gtr:impact><gtr:outcomeId>r-713955471.9570609c6b2f684</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>BSR-VP6 cell line stability</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Replication-deficient vaccine strains were tested in animals as monovalent or in multivalent combinations and the protection analysed by Elisa and serum neutralisation assays.</gtr:description><gtr:id>37CBCE78-BCAB-4582-B5B8-ED1BC789EEF5</gtr:id><gtr:impact>Testing these virus vaccine strains is essential to support them for commercial development</gtr:impact><gtr:outcomeId>58a45bf7e914f8.65079507</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Evaluation of vaccine efficacy</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>855CF1CA-35FF-437E-B08F-DA553D71F86B</gtr:id><gtr:title>Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0426397721102f497683322c8fd55ed7"><gtr:id>0426397721102f497683322c8fd55ed7</gtr:id><gtr:otherNames>Celma CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5899a869ba1f99.34535982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>620F774D-E8A1-44DD-94A7-F12F774DD136</gtr:id><gtr:title>Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0426397721102f497683322c8fd55ed7"><gtr:id>0426397721102f497683322c8fd55ed7</gtr:id><gtr:otherNames>Celma CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461e7f6e59d15.04359749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>473D0B43-9184-4D98-9996-D149348F3445</gtr:id><gtr:title>Generation of infectious RNA complexes in Orbiviruses: RNA-RNA interactions of genomic segments.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ddc1c9b4c75e0da902aa4b8eacb27e2"><gtr:id>1ddc1c9b4c75e0da902aa4b8eacb27e2</gtr:id><gtr:otherNames>Fajardo T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5899a8f0e3b573.15141544</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>972AAEB6-6941-492D-91F9-B66A6215F13A</gtr:id><gtr:title>Pathogenicity study in sheep using reverse-genetics-based reassortant bluetongue viruses.</gtr:title><gtr:parentPublicationTitle>Veterinary microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0426397721102f497683322c8fd55ed7"><gtr:id>0426397721102f497683322c8fd55ed7</gtr:id><gtr:otherNames>Celma CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-1135</gtr:issn><gtr:outcomeId>5461e7f693e581.35489912</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/J021342/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>